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Abstract
Background: Antiretroviral scale-up is increasing in resource-constrained settings. To date, few studies have
explored the barriers and facilitators of adherence to ART in these settings. Facilitators and barriers of antiretroviral
adherence in Peru are not completely understood.
Methods: At two clinics that serve a large number of HIV-positive individuals in Lima, Peru, 31 in-depth interviews
were carried out in 2006 with adult HIV-positive individuals receiving ART. Purposive sampling was used to recruit
the participants. Interviews were transcribed and coded using two Spanish-speaking researchers and a content
analysis approach to identify themes in the data.
Results: Among the participants, 28/31 (90%) were male, 25/31 (81%) were self-identified as mestizo, and 19/31
(61%) had an education above high school. The most frequently discussed barriers to adherence included side
effects, simply forgetting, inconvenience, dietary requirements, being away from home, and fear of disclosure/
stigma. The most frequently discussed facilitators to adherence included having a fixed routine, understanding the
need for compliance, seeing positive results, treatment knowledge, and faith in treatment.
Conclusions: Overall, these findings were similar to the facilitators and challenges experienced by individuals on
ART in other resource constrained settings. Further treatment support tools and networks should be developed to
decrease the challenges of ART adherence for HIV-positive individuals in Lima, Peru.
Background
Individuals living with HIV/AIDS in resource-con-
strained settings now have increased access to antiretro-
viral therapy (ART) medications. In Peru, the HIV/AIDS
epidemic has been largely concentrated among men
who have sex with men (MSM) [1,2]. The seropreva-
lence for MSM is 10-22% [2-4], compared to 0.1-0.4%
for the general population [5], and 1% for female sex
workers [6]. Antiretroviral therapy, available through the
national ART program in Peru since 2004 [1,7], is a key
component of improving health outcomes for HIV-posi-
tive individuals. To achieve optimal results from ART,
high levels of patient adherence to ART are critical
[8-10]. The availability of ART allows HIV patients to
be managed effectively as a serious chronic rather than
terminal illness [8,11].
Adherence plays an important role in the effectiveness
of ART because individuals who demonstrate lower
levels of adherence are at greater risk for increased
levels of morbidity, treatment failure, and the develop-
ment of drug resistant forms of HIV [12-16]. To achieve
optimal effectiveness for reducing viral load, patients
take 90-95% of their prescribed antiretroviral medica-
tions [14]. However, viral suppression may still occur
with lower levels of mean adherence, from 54% - 100%,
to potent regimens [17]. When viral load rises, risk of
transmission increases [18] and the quality and longevity
of life decreases [19,20].
Studies have shown that a large percentage of patients,
in general, find it difficult to achieve high levels of
adherence to a treatment. In a meta-analysis of 569 stu-
dies, patients display a non-adherence rate of approxi-
mately 25% on average [21]. Non-adherence is
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particularly difficult for HIV-positive individuals because
ART regimens are complicated, have complex side
effects, and associated stigma. Past studies have shown
that approximately 12-50% of HIV-positive patients fail
to achieve optimal adherence [22-27]. In a meta-analysis
of adherence to ART that included 37 qualitative studies
and 47 quantitative studies in developed and developing
nations, Mills et al. (2006) found that many barriers to
adherence were reported similarly in a number of set-
tings and countries. Of the 37 qualitative studies that
were conducted, only two qualitative studies were car-
ried out in developing countries [28]. In Peru, adherence
to HIV risk reduction and treatment is becoming
increasingly problematic according to anecdotal reports
from local AIDS clinicians.
To provide optimal HIV care, strategically developed
interventions that are tailored and multi-focused are
needed to improve ART adherence. However, the devel-
opment of effective and tailored interventions to
improve ART adherence requires an in-depth under-
standing of the mutable factors that influence it. Few
qualitative studies have been carried out in resource
constrained international settings [28] and there have
not been any in-depth qualitative studies conducted in
Lima, Peru related to the barriers and facilitators for
ART adherence.
The present study describes the social, cultural,
knowledge-based, and logistical factors that influence
ART adherence in Peru. Heightened knowledge of these
specific barriers and facilitators for ART adherence in
Peru will aid in the development of useful and needed
interventions to promote improved ART adherence in
resource constrained settings.
Methods
Formative research techniques were carried out to assess
adherence barriers and facilitators towards ART medica-
tion in Lima, Peru. This was done using in-depth inter-
views with adult HIV-positive people receiving ART and
clinical services at two community-based clinics
(Impacta and Via Libre). We also addressed access, use,
and perceptions of the Internet, cell phones, and PDAs
as a means for health promotion that were reported in a
separate study [29].
Both of these clinics primarily serve male clients
(100% at Impacta, approximately 80% at Via Libre) and
demonstrate similar demographic profiles for their
patient populations. These two clinics were selected
because they are two of the most important clinics for
HIV positive individuals in Lima and they have partici-
pated in other research studies. Purposive sampling was
employed at the two clinics to recruit individuals for
study participation [30]. In addition, flyers were posted
at the clinics to recruit participants into the study over
the course of six months. To qualify for the study, parti-
cipants had to be at least 18 years old, HIV positive, and
receiving ART.
Past studies informed the development of the topic
guide for the semi-structured in-depth interviews
[31,32]. The topic guide was then reviewed for content
validity by HIV consultants in Lima. An outline of ques-
tions related to lifestyle, living with HIV, ART medica-
tion are listed below:
Lifestyle
Describe a normal day in your life.
• With whom are you living right now?
• Who are the important people in your life?
• What are your major concerns right now?
Living with HIV
• When did you first find out you were HIV positive?
What was that like for you? Has HIV changed your life?
• Have you told anyone in your life about your HIV
status? Why or why not? If yes, what was their reaction?
• What sources of support for living with HIV have
you been able to find?
ART Medication
• What have you heard about medicines that are used to
treat HIV/AIDS (antiretrovirals)? How is it that they
work in the body?
• What have you heard about ‘HIV viral load’? What
have you heard about ‘CD4’ (good immune cells)?
• How well do you think these medicines help people
with HIV/AIDS?
• Do you believe these medicines harm people with
HIV/AIDS? Why?
• How long have you been on these medicines? How
has that been for you? Have you had any problems on
these medicines?
• How important do you think it is to take all of your
doses of this medication? What happens if people miss
doses?
• Has your day-to-day life had to change to take these
medicines? How?
There are certain ways people are told to take these
medicines. For example, take a certain number of pills
at a certain time of day.
• How has it been for you to take these medicines this
way?
• What makes it hard to take these medicines? (cost,
transportation, childcare, stigma?)
• What helps you take these medicines? (pill boxes,
daily routine, reminders, regular meal times, privacy,
support of friends or family, not drinking as much
alcohol?)
• How serious is it to have HIV now that medicines to
treat people with HIV/AIDS are here?
The in-depth interviews were carried out by an experi-
enced and trained psychologist in each of the clinics
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(Impacta and Via Libre). After giving consent, all inter-
views were conducted in Spanish with each respondent
in a private room for approximately one hour. Each
interview was tape-recorded. All participants signed an
informed consent form prior to entry into the study.
Participants were compensated with 30 soles (about 10
dollars) for travel expenses.
Audio files were transcribed and transcripts were
reviewed by a Spanish-speaking investigator (WC) for
initial text element and key word coding. Transcripts
were then reviewed separately by two Spanish-speaking
authors (WC and DK) for text element and key word
coding, and initial generation of themes. The coding of
the text into categories of experiences and beliefs
resulted in the emergence of thematic concepts. A
theme was then defined as a “common thread that runs
through the data” [33]. Summaries of coding practices
and thematic concepts were compared and discussed
over 10 meetings until a consensus was reached on
which themes were most salient to participants’
responses. We then reviewed the transcripts to confirm
our findings until we reached saturation and identified
quotes that best illustrate common theme [34]. Quotes
were edited for ease of reading but were not substan-
tially altered. Data were entered into Atlas.ti version 5.5
(2008) qualitative data management software (Scientific
Software Development, Berlin, Germany) for theme
identification using a content analysis approach. The
study had ethical approval from the University of
Washington Human Subjects Division (HSD# 06-1430-
G-01) and the institutional review boards of Via Libre
and Impacta.
Results
Description of Study Participants
During March-August 2006, 31 people living with HIV
were interviewed, 16 at Via Libre Clinic and 15 at
Impacta Clinic. Of these participants, 28/31 (90%) were
male, 25/31 (81%) were self-identified as mestizo (multi-
ethnic and/or multi-racial), and 19/31 (61%) had an
education level above high school. All participants were
currently on ART.
ART Adherence Facilitators
In general, participants who were able to describe the
effects of the medication appeared to be more conform-
able with adhering to the regimen. This “information”
element has been theorized to be an important compo-
nent in ART adherence [35] and is an area that health
professionals are well qualified to address. For many
people, overcoming the side effects of ART was the first
stage that must be addressed to achieve high levels of
adherence. The second stage for many individuals was
successfully incorporating ART into one’s every day
routine. Participants reported a number of specific fac-
tors that influenced improved levels of adherence to
ART.
Patient Characteristics
First, many factors were identified that relate to indivi-
dual level patient characteristics that represented facili-
tators to improved ART adherence. These include
seeing positive results (reported by 65% of participants,
20/31), learning to manage (reported by 55% of partici-
pants, 17/31), and self-efficacy for high levels of adher-
ence to the ART regimen (reported by 32% of
participants, 10/31). Seeing positive results and learning
to manage were two of the most frequently discussed
adherence facilitators by the participants in this study at
the patient characteristics level. Participants who knew
that ART was positively impacting their health and
those who learned to manage the impact of ART regi-
mens on their everyday lives reported these characteris-
tics as important ART adherence facilitators.
An example of learning to manage is expressed by this
participant:
“I made antiretrovirals part of my life. It’s true that
the pills make me sick, but after some time the [bad
sensation/pain] that I felt is something that is not
impossible to manage.” Male, white, 43 years
Examples of seeing positive results were expressed by
these participants:
“The antiretrovirals have helped me to increase my
CD4 from 170 to 230 and not only that but also
improve my spirit.” Male, mestizo, 28 years
“Taking the antiretrovirals helps a lot. I can see for
myself: Before I started the treatment, I weighed 52
kilos and now I am at 74 kilos. I believe that the
treatment helps because in some way I am seeing
the results.” Male, white, 48 years
An example of self-efficacy to adhere to ART is
expressed by this participant:
“What makes me take my antiretroviral medicines is
my spirit. My spirit tells me always that I have to take
my pills to feel good with myself.” Male, mestizo, 25
years
Beliefs about the Medication
Second, many factors were identified that relate to
beliefs about the medication that related to improved
levels of adherence. These include beliefs in efficacy of
drugs (reported by 42% participants, 13/31), faith in
treatment (reported by 42% participants, 13/31), and
understanding the need for compliance (reported by
97% participants, 30/31). Specifically, understanding the
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need for compliance was one of the most frequently dis-
cussed facilitators to adherence in this study as
expressed on one participant:
“If I want to continue living, I have to adhere to the
treatment because it is the only way to be healthy.
This is like a diabetic patient. If he/she does not
take their medicine, he/she will die. It’s not because
of the sugar but because all that occurs when the
sugar increases.” Male, white, 48 years
Participants who were aware of the need for compliance
to their medication regimens were more likely to cite this
factor as key to increasing self-motivation for adherence.
Other participants expressed belief in the efficacy of
the drugs and a strong faith in treatment that facilitated
motivation for adherence. One participant states:
“Taking my antiretrovirals will make me feel good, I
know that I will not be cured, but will help me to
live longer.” Female, mestizo, 38 years
Another participant expresses:
“Antiretroviral medicines give me the opportunity to
continue living, to continue being with my friends
and family.” Male, white, 43 years
Daily Schedules
Third, many factors were identified that relate to daily
schedules were associated with strategies for improved
levels of adherence. These include having a fixed routine
(reported by 71% participants, 22/31), and the use of
reminder tools (reported by 58% participants, 18/31).
Having a fixed routine was the top adherence facilitator
that was discussed by participants as related to daily
schedules. As expressed by one participant:
“I have my brain alarm, when it’s time to take my
antiretroviral pills it starts to buzz... it’s eight...time
to take your pill.” Male, mestizo, 35 years
Many participants reported concrete strategies to suc-
cessfully integrate their pill taking regimens into their
lives as key facilitators to adherence such as the use of
reminder tools:
“I have programmed the alarm of my cell phone,
with a very nice ring tone. When it rings I know
automatically that I have to go where my pills are
and take them.” Male, mestizo, 36 years
Interpersonal Relationships
Lastly, a number of factors were identified that relate to
interpersonal relationships that helped improve levels of
adherence. These include family and friends reminding
the participants to adhere to their ART regimen
(reported by 29% participants, 9/31), and living for
someone (reported by 16% participants, 5/31). As
expressed by two participants:
“My mom or my sister remind me to take my medi-
cines. For example, my sister tells me “have you
taken your “contrita” (a popular name for the medi-
cine)? So I respond ‘yes, I took my ‘contrita’.” Male,
mestizo, 34 years
“I live for my daughter, for her, I try to get through.”
Female, mestizo, 38 years
Many participants reported that the support of others,
including their health care provider (e.g. doctor, nurse,
counsellor), in their lives was an important and effective
adherence facilitator. As represented by the following
experience noted by a participant:
“My new doctor is more worried about me...we are
working together. We have changed my medication
and I feel completely relieved.” Male, mestizo, 36
years
Other Facilitators
Many other ART adherence facilitators that were briefly
discussed by participants include the following. Many
participants reported positive and open relationships
with their medical providers as an important adherence
facilitator (reported by 39% participants, 12/31). Feeling
comfortable asking questions, talking about challenges,
and feeling a part of decision making with one’s medical
provider played a key role in facilitating adherence.
Next, having a simple regimen was reported by a few
participants as assisting in ART adherence. Lastly, medi-
cation taking priority over substance use, accepting HIV
status, and being open with disclosure of HIV status
were noted by a few participants as important adherence
facilitators.
ART Adherence Barriers
A wide variety of barriers to ART adherence were dis-
cussed by the participants. These were classified into
three broad categories: patient characteristics, beliefs
about medications, and daily schedules.
Patient Characteristics
First, patient characteristics include the following fac-
tors: simply forgot (reported by 36% participants, 11/31);
fear of disclosure/stigma (reported by 23% participants,
7/31); and financial constraints (reported by 13% partici-
pants, 4/31). Simply forgetting one’s medication was one
of the most frequently cited adherence barriers by the
participants within the category of patient characteris-
tics. As represented by this participant’s experience:
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“I think that forgetting to take your medicines is that
you simply miss the time, because you know that
you have to follow a scheme, to follow a treatment,
but there were moments that I had to take the pill
and I missed it.” Female, white, 32 years
The participants also discussed difficulties with adher-
ing to medication regimens without disclosing their HIV
status to others at work and/or at home. A number of
participants touched on this barrier:
“Initially, I took my treatment in a particular way. It
was my cross, nobody knew about it, nobody, during
five years, nobody, nobody knew about it, only my
physician and me.” Male, white, 48 years
“I have to hide from my family so they do not know
that I’m taking my ART medication. They do not
know anything about my disease.” Male, mestizo, 36
years
“One time I had a pill box, a hexagon, but it was...
very big, and they asked me: hey, ‘what are those
pills?’ ‘ah, they are vitamins’.” Male, mestizo, 27
years
In addition, financial constraints and fear of disclo-
sure/stigma were also frequently discussed. Specifically,
participants noted financial challenges related to acquir-
ing their medications on time. One participant remarks:
“The problem with taking my pills was always eco-
nomic. At the beginning it was very expensive, then
prices went down. Because of this, it is very difficult
to maintain an exact frequency for taking my pills
and I had holes in the treatment.” Male, mestizo, 39
years
Beliefs about the Medication
Second, beliefs about the medication were discussed as
barriers to ART adherence by the participants. This
category included the following factors: side effects (real
or anticipated) reported by 74% participants, 23/31;
harmful (reported by 19% participants, 6/31); and not
convinced of efficacy (reported by 16% participants, 5/
31). Overall, side effects were the most frequently dis-
cussed barrier to adherence by participants. Side effects
included both negative symptoms that the participant
attributed to the ART regimen and side effects that
were anticipated to occur due to the ART regimen. As
highlighted by one participant:
“When I started with the treatment I was nauseous
all the time. I had headaches. I had a fever. I had
cellulitis again. I experienced a lot of illnesses that I
had never had before....I was very very bad off.”
Male, white, 43 years
Daily Schedules
Lastly, daily schedules were reported as additional
challenges to ART adherence. This category includes
the following factors: dietary requirements difficult to
balance (reported by 26% participants, 8/31); being
away from home (reported by 23% participants, 7/31);
and too busy (reported by 16% participants, 5/31).
Specifically, being away from one’s household during
the course of one’s day for work or social engage-
ments was reported as greatly interfering with adher-
ence to the ART regimen. As discussed by three
participants:
“I have forgotten to take my pills when I go out in a
hurry out of my house or when I had to stay at
work. When the time to take my pill passed (8 pm),
and I thought: ‘oops...my pill...I didn’t take it’.” Male,
mestizo, 35 years
“For me, weekends are terrible because I have to go
out to a party or a meeting and I do not take the
pill at night. It is a problem for me.” Male, mestizo,
28 years
“I have to take my pills with food. This is the pro-
blem and what makes me upset is that there are
some days that I cannot eat and I cannot take my
pills.” Male, mestizo, 35 years
A few other participants found the dietary require-
ments difficult to balance:
“I have to pay attention to my diet and there are
some times that I cannot control it. This makes it a
little bit difficult to take my pill.” Male, mestizo, 36
years
In addition, a number of participants felt that they
were too busy to remember their pills. As expressed by
one individual: “There are some times that I have so
many things in my head that I forget to take my pills.”
Male, white, 35 years
Other Barriers
Other barriers to ART adherence that were briefly dis-
cussed by the participants included the following. Some
participants lacked trust in their medical provider and
felt that this was a barrier to adherence. Some were feel-
ing healthy so they did not see the need to adhere to
their ART regimens. Others felt hopeless and not moti-
vated to adhere to their ART regimens. A few others
reported that because ART caused unwanted changes to
their body, they were reluctant to adhere to the regimen.
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Lastly, the size of the pill hindered adherence and that
substance use takes priority over ART adherence was
reported by a few participants.
Discussion
To our knowledge this is the first in-depth qualitative
study on adherence facilitators and barriers of ART
medication adherence among people living with HIV in
Lima, Peru. Our study identified that having a fixed rou-
tine, understanding the need for compliance, seeing
positive results, knowledge of treatment, faith in treat-
ment, and use of reminders tools were the most fre-
quently cited facilitators. In addition, side effects, simply
forgetting, inconvenient schedule, financial constraints,
being away from home, and fear of disclosure/stigma
were the most frequent cited barriers.
The results of this study are similar to those of other
qualitative studies in developing countries [28]. For
example, in a study conducted in Brazil, Brigido et al.
(2001) reported that forgetfulness and intolerance were
the most frequent reasons for non-adherence. Other
reasons cited were stopping ART to consume alcohol,
misunderstanding of the prescription requirements, diffi-
culty in following recommendations at the workplace,
and lack of money for transportation to obtain medica-
tion [36]. In Botswana, Weiser et al. (2003) found that
the principal barriers to HIV adherence were financial
constrains, stigma, travel/migration, and side effects
[37]. In our study, we did not find that migration was a
barrier. In Uganda, Byakika-Tusiime (2005) et al.
reported that shortage of drugs due to lack of money
was the most common reason for non-adherence. Other
reasons included forgetfulness, drug inaccessibility,
adverse effects of the drugs, travelling away from home,
unclear instructions by the health provider, and being
too busy [38]. In another study conducted in Brazil, Pin-
heiro et al. (2002) found that self-efficacy expectation,
the perception of negative effects, and physical concerns
were associated with adherence [39].
Similarly, in a qualitative study conducted with Span-
ish-speaking patients in Los Angeles, Murphy et al.
(2003) reported that the most frequent barriers for non-
adherence were feeling depressed or feeling over-
whelmed, simply forgot, and timing difficulties. Our
study, however, did not find feeling depressed/stressed
as a common barrier. In the same study, the most fre-
quently identified adherence strategies were making an
effort to learn more about the antiretroviral medications,
accepting the need to take antiretroviral medications,
and refilling prescriptions early or on time [40].
Lastly, a number of studies have found that patients
with a trusting and open relationship with their health
care providers are better able to adhere to their ART
regimens [28]. Furthermore, patients who lack open
communication with their health care providers due to
cultural differences, cultural insensitivity, and/or lan-
guage barriers may find it difficult to adhere to ART
regimens [41].
Effective interventions to improve adherence to ART
are able to build on adherence facilitators and address
adherence barriers. For example, one study at 6 HIV
specialty clinics in California that included 437 HIV
positive participants, it was demonstrated that partici-
pants who participated in a clinic-wide intervention
included a brief counselling session with their medical
provider that established open communication, built
trust, and addressed obstacles to complying with pill
taking regimens were more likely to remain adherent to
ART [42]. In a review of behavioral interventions that
promote ART adherence, Simoni et al. (2008) found
that there are a number of specific strategies that may
be effective at promoting adherence provided that they
are culturally sensitive and address structural and indivi-
dual level barriers. These strategies include solidifying
the patient-provider relationship by establishing trust,
promoting social support, employing simple practical
strategies, managing side effects, and addressing misin-
formation related to adherence practices [43].
In Lima, HIV positive individuals may be in particular
need of ART adherence interventions that address stra-
tegies to improve adherence through the patient-provi-
der relationship and improve strategies to incorporate
ART pill taking regimens into a busy urban lifestyle
where individuals may feel stigmatized by their HIV
positive status. One effective strategy that may address
these factors in an environment such as Lima, Peru may
involve the use of cell phones. Cell phones have been
successfully used to support patient medication adher-
ence in developed countries [44] and in resource-con-
strained settings such as Uganda [45], and South Africa
[46]. In Peru, Curioso et al. are currently evaluating a
one-year randomized trial, Cell-POS http://www.cellpos.
org, a computer-based intervention using cell phones
(via short text messages) to enhance adherence to anti-
retroviral treatment (ART) and support HIV care
among adult HIV- positive patients. Cell phones might
be an ideal tool to improve ART adherences for HIV
patients in Lima because they can be private, interactive,
efficient, affordable, convenient, and useful as a remin-
der tool [47,48].
Our study was limited by its use of a convenience
sample of people living with HIV/AIDS in an urban
population of Lima. The participants in this study can-
not be considered representative of people living with
HIV/AIDS throughout Peru. However, one of the
strengths of this study is that we are confident that we
reached saturation because a number of the themes
were similar among participants.
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Additional qualitative and quantitative studies are
needed in Peru that further explore the barriers and
facilitators of ART adherence for women and other
demographic groups in Lima and for Peruvians living in
other rural and urban regions of Peru. Specifically, more
research is need on strategies to improve adherence for
sex workers who experience high rates of HIV infection.
In addition, more research is needed to understand
what mechanisms support the transition from managing
the ART regimen and side effects to successfully inter-
nalizing self-care to achieve high levels of ART adher-
ence. Multi-component, tailored intervention programs
that specifically address the barriers of ART adherence
and build on the facilitators of ART adherence in Peru
should be developed and pilot tested at clinics and
health care facilities that provide ART. Lastly, in Peru,
more widespread public health education campaigns are
needed to decrease HIV/AIDS stigma and to increase
community acceptance of individuals living with HIV/
AIDS. Additional public health programs are needed to
increase levels of direct interpersonal social support net-
works for individuals living with HIV who are on ART.
Conclusions
Overall, these findings were similar to the facilitators
and challenges experienced by individuals on ART in
other resource constrained settings. However, this is the
first study to use qualitative methods to investigate fac-
tors related to ART adherence in Lima, Peru. The find-
ings from our study can be used to inform the
development of effective interventions that address the
barriers and facilitators of ART adherence in Peru. Spe-
cifically, highlighting positive health results due to the
ART treatment regimen with patients, developing effec-
tive reminder tools, and promoting faith in treatment
may improve levels of ART adherence in Lima. Further-
more, helping patients to physically and emotionally
manage ART side effects, to improve strategies for
incorporating ART regimens into their daily lives, and
for alleviating financial constraints to adherence to ART
will also improve long term ART adherence for HIV
positive patients in Lima.
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